ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers
Sponsor: Abbott
This PHASE2 trial investigates BRCA1 Gene Mutation and Breast Cancer and is currently completed. Abbott leads this study, which shows 13 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 8 earlier versions
-
Jun 2021 — Jan 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
- Steven J Isakoff, MD, PhD
For direct contact, visit the study record on ClinicalTrials.gov .